Supporting Information

Novel Isochroman Dimers from *Stachybotrys* sp. PH30583:
Fermentation, Isolation, Structural Elucidation and Biological Activities

Wei Li\(^1,2^*,\) Ya-Bin Yang\(^1^*,\) Xue-Qiong Yang\(^1\), Hui-Ding Xie\(^2\), Zhi-Hui Shao\(^1\), Hao Zhou\(^1\), Cui-Ping Miao\(^3\), Li-Xing Zhao\(^3\), Zhong-Tao Ding\(^1\)

\(^{*}\)W. Li and Y. B. Yang contributed equally to this paper.

Affiliations

\(^1\)School of Chemical Science and Technology, Yunnan University, Kunming, China
\(^2\)School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, China
\(^3\)Yunnan Institute of Microbiology, Yunnan University, Kunming, China

Correspondence

*Prof. Dr. Zhongtao Ding*

School of Chemical Science and Technology
Yunnan University
Kunming 650091
People’s Republic of China
Phone: 86-871-65033910
zt ding@ynu.edu.cn
Table of Contents

Fig. 1S HPLC chromatography spectra of mixtures of compounds 1-3, 6-10 and samples from each day ................................................................. 4

Fig. 2S The chiral HPLC chromatography spectra of compounds 2, 3, 7, 8, 9 and 10 ............ 6

Fig. 3S Lowest-energy conformers of stachydein and stachiol with different configurations ... 6

Table 1S Cytotoxicity activity (IC_{50}, μM) assay of compounds (7, 8) ........................... 6

1. NMR Spectra, HR-ESIMS and CD (Methines in DEPT: three upward signals, methylenes in DEPT: downward signals, and methyls in DEPT: two upward signals in DEPT spectra) .... 7

Fig. 4S $^1$H NMR spectrum of 1 in CDCl$_3$ ........................................................................ 7

Fig. 5S $^{13}$C NMR spectrum of 1 in CDCl$_3$ ........................................................................ 7

Fig. 6S $^1$H NMR spectrum of 2 and 3 in CDCl$_3$ ................................................................. 8

Fig. 7S $^{13}$C NMR spectrum of 2 and 3 in CDCl$_3$ ................................................................. 8

Fig. 8S HSQC spectrum of 2 and 3 in CDCl$_3$ ................................................................. 9

Fig. 9S HMBC spectrum of 2 and 3 in CDCl$_3$ ................................................................. 9

Fig. 10S HR-ESIMS of 2 and 3 ........................................................................................................ 10

Fig. 11S $^1$H NMR spectrum of 4 and 5 in MeOD ............................................................... 10

Fig. 12S $^{13}$C NMR spectrum of 4 and 5 in MeOD ............................................................... 11

Fig. 13S HSQC spectrum of 4 and 5 in MeOD ............................................................... 11

Fig. 14S HMBC spectrum of 4 and 5 in MeOD ............................................................... 12

Fig. 15S HR-ESIMS of 4 and 5 ........................................................................................................ 12

Fig. 16S $^1$H NMR spectrum of 6 in CDCl$_3$ ........................................................................ 13

Fig. 17S $^{13}$C NMR spectrum of 6 in CDCl$_3$ ........................................................................ 13

Fig. 18S HSQC spectrum of 6 in CDCl$_3$ ............................................................................. 14

Fig. 19S HMBC spectrum of 6 in CDCl$_3$ ............................................................................. 14

Fig. 20S HR-ESIMS of 6 ........................................................................................................... 15

Fig. 21S $^1$H NMR spectrum of 7 and 8 in CDCl$_3$ ............................................................. 15

Fig. 22S $^{13}$C NMR spectrum of 7 and 8 in CDCl$_3$ ............................................................. 16

Fig. 23S HSQC spectrum of 7 and 8 in CDCl$_3$ ..................................................................... 16

Fig. 24S HMBC spectrum of 7 and 8 in CDCl$_3$ ..................................................................... 17

Fig. 25S HR-ESIMS of 7 and 8 .................................................................................................... 17

Fig. 26S $^1$H NMR spectrum of 9 and 10 in CDCl$_3$ ............................................................ 18
Fig. 27S $^{13}$C NMR spectrum of 9 and 10 in CDCl$_3$...
Fig. 28S HSQC spectrum of 9 and 10 in CDCl$_3$.......................... 19
Fig. 29S HMBC spectrum of 9 and 10 in CDCl$_3$.......................... 20
Fig. 30S HR-ESIMS of 9 and 10.................................................. 20
Fig. 31S CD spectrum of 9 and 10.................................................. 21
Fig. 1S HPLC traces of a reference mixture of compounds 1-3, 6-10, and of samples from fermentation days 4 to 7.
Dianistach (9, 10)

Distachydeins (7, 8)
**Fig. 2S** Chiral HPLC traces of compounds 2, 3, 7, 8, 9, and 10

![Chiral HPLC traces](image)

(R)- stachydein  
(S)- stachydein

(R)- stachiol  
(S)- stachiol

**Fig. 3S** Lowest-energy conformers of stachydein and stachiol with different configurations.

**Table 1S** Cytotoxicity activity (IC\(_{50}\), μM) assay of compounds (7, 8).

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>HL-60</th>
<th>SMMC-7721</th>
<th>A-549</th>
<th>MCF-7</th>
<th>SW480</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7, 8</strong></td>
<td>&gt; 40</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
<td>&gt; 40</td>
</tr>
<tr>
<td><strong>Taxol</strong></td>
<td>&lt; 0.008</td>
<td>&lt; 0.008</td>
<td>&lt; 0.008</td>
<td>&lt; 0.008</td>
<td>&lt; 0.008</td>
</tr>
</tbody>
</table>
1. NMR Spectra, HR-ESIMS and CD (Methines in DEPT: three upward signals, methylenes in DEPT: downward signals, and methyls in DEPT: two upward signals in DEPT spectra).

Fig. 4S $^1$H NMR spectrum of 1 in CDCl$_3$.

Fig. 5S $^{13}$C NMR spectrum of 1 in CDCl$_3$. 
Fig. 6S $^1$H NMR spectrum of 2 and 3 in CDCl$_3$.

Fig. 7S $^{13}$C NMR spectrum of 2 and 3 in CDCl$_3$. 
Fig. 8S HSQC spectrum of 2 and 3 in CDCl₃.

Fig. 9S HMBC spectrum of 2 and 3 in CDCl₃.
Fig. 10S HR-ESIMS of 2 and 3.

Fig. 11S $^1$H NMR spectrum of 4 and 5 in MeOD.
Fig. 12S $^{13}$C NMR spectrum of 4 and 5 in MeOD.

Fig. 13S HSQC spectrum of 4 and 5 in MeOD.
Fig. 14S HMBC spectrum of 4 and 5 in MeOD.

Fig. 15S HR-ESIMS of 4 and 5.
Fig. 16S $^1$H NMR spectrum of 6 in CDCl$_3$.

Fig. 17S $^{13}$C NMR spectrum of 6 in CDCl$_3$. 
Fig. 18S HSQC spectrum of 6 in CDCl₃.

Fig. 19S HMBC spectrum of 6 in CDCl₃.
Fig. 20S HR-ESIMS of 6.

Fig. 21S $^1$H NMR spectrum of 7 and 8 in CDCl$_3$. 
Fig. 22S $^{13}$C NMR spectrum of 7 and 8 in CDCl₃.

Fig. 23S HSQC spectrum of 7 and 8 in CDCl₃.
Fig. 24S HMBC spectrum of 7 and 8 in CDCl₃.

Fig. 25S HR-ESIMS of 7 and 8.
Fig. 26S $^1$H NMR spectrum of 9 and 10 in CDCl$_3$. 
Fig. 27S $^{13}$C NMR spectrum of 9 and 10 in CDCl$_3$.

Fig. 28S HSQC spectrum of 9 and 10 in CDCl$_3$. 
Fig. 29S HMBC spectrum of 9 and 10 in CDCl₃.

Fig. 30S HR-ESIMS of 9 and 10.
Fig. 31S  CD spectrum of 9 and 10.